Abstract
Severity (acute-care hospitalization), criticality (ICU hospitalization), and fatality of SARS-CoV-2 Beta (B.1.351) variant was investigated through case-control studies applied to complete national cohorts of infection, disease, and death cases in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher. Findings highlight risks to healthcare systems, particularly to intensive care facilities and resources, with increased circulation of Beta.
Introduction
Commencing in mid-January, 2021, Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Alpha (B.1.1.7) variant wave that peaked in the first week of March [1–5], but was immediately followed by a Beta (B.1.351) variant wave that peaked in the first week of April [1–5]. This created a unique epidemiologic situation that allowed comparative assessment of the severity, criticality, and fatality of these two variants.
Methods
We investigated severity (acute-care hospitalization) [6], criticality (ICU hospitalization) [6], and fatality [7] of both variants through eight case-control studies applied to the complete national cohorts of SARS-CoV-2 infections, Coronavirus Disease 2019 (COVID-19) disease cases, and COVID-19 deaths in Qatar, a country with diverse demographics where 89% of the population comprises expatriates from over 150 countries [8]. Data on polymerase chain reaction (PCR) testing and clinical characteristics were extracted from the national, federated COVID-19 databases that have captured all SARS-CoV-2–related data since the start of the epidemic. These databases were retrieved from the integrated nationwide digital-health information platform (universal healthcare system), and include all records of PCR testing, antibody testing, vaccinations, COVID-19 hospitalizations, infection severity classification, and COVID-19 deaths. Databases are complete at the national level with no missing information.
Records of PCR testing and clinical data for hospitalized COVID-19 patients were examined. Details of the laboratory methods for PCR testing are found in Supplementary Text 1. Each person that had a positive PCR test result and hospital admission was subject to an infection severity assessment every three days until discharge or death. Individuals who progressed to COVID-19 disease between the time of the positive PCR test result and the end of the study were classified based on their worst outcome, starting with death [7], followed by critical disease [6], and then severe disease [6].
Cases in the case-control studies were persons who progressed to COVID-19 severe disease, critical disease, or death. Controls were persons with asymptomatic or mild SARS-CoV-2 infections. Cases and controls were matched at a ratio of 1:3 by 10-year age group, sex, and bi-weekly interval of the PCR diagnosis date. Every case in Qatar that met the inclusion criteria and that could be matched to a control was included in the study. Classification of case severity, criticality, and fatality followed the World Health Organization guidelines [6, 7], and assessments were made by trained medical personnel through individual chart reviews. Details of the COVID-19 severity, criticality, and fatality classification are found in Supplementary Text 2.
From January 18 until February 15, 2021, the Alpha variant wave expanded rapidly and weekly rounds of viral genome sequencing [1–4] of randomly collected samples confirmed the presence of this and other originally circulating “wild-type” variants, but documented only limited presence of the Beta variant and no other variants of concern [1–4]. This allowed a comparative assessment for the Alpha variant versus wild-type variants during this specific timeframe (Supplementary Text 3). From March 8 through May 31, 2021, the Beta variant wave expanded rapidly and viral genome sequencing [1–4] and multiplex quantitative reverse-transcription PCR (RT-qPCR) variant screening [1–5] indicated dominance of the Beta and Alpha variants, with limited presence of other variants [1–5]. This enabled comparisons between the Beta versus Alpha variants during this specific timeframe (Supplementary Text 3). The Delta [9] (B.1.617.2) variant has been introduced only recently in Qatar, and it remains at low incidence as of July 11, 2021 [3–5]. Further details on the classification of infections by variant type are found in Supplementary Text 3.
Descriptive statistics (frequency distributions and measures of central tendency) were used to characterize the study samples. Two-sided p-value of <0.05 was considered statistically significant. The odds ratio and its associated 95% confidence interval (CI) were calculated using the exact method. Confidence intervals were not adjusted for multiplicity. Interactions were not investigated. Two sensitivity analyses were conducted by first adjusting for age, and second by adjusting for age and sex, in logistic regression analyses. Statistical analyses were conducted in STATA/SE version 17.0.
The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent. Reporting of the study followed the STROBE guidelines (Supplementary Table 1).
Results
Demographic characteristics of the samples for each disease outcome in assessing the severity, criticality, and fatality of the Alpha variant compared to the wild-type variants are presented in Supplementary Table 2. Compared to wild-type variants, the odds of progressing to severe disease were 1.48-fold (95% CI: 1.18-1.84) higher for the Alpha variant (Table 1). The odds of progressing to critical disease were 1.58-fold (95% CI: 0.79-3.10) higher, but did not reach statistical significance. There were too few COVID-19 deaths to assess the fatality of the Alpha variant.
Infection severity, criticality, and fatality of the Alpha and Beta variants in the population of Qatar.
Demographic characteristics of the samples for each disease outcome in assessing the severity, criticality, and fatality of the Beta variant compared to the Alpha variant are presented in Supplementary Table 3. Compared to the Alpha variant, the odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for the Beta variant (Table 1). The odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. The odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher. Sensitivity analyses confirmed the above results (Supplementary Table 4).
Discussion
The Alpha variant presented a 48% higher risk of severe disease than wild-type variants in the population of Qatar, affirming its greater gravity [10, 11] (odds ratio approximates risk ratio for rate outcomes). Infection with the Beta variant was associated with even greater risks of severe and critical disease and COVID-19 death, affirming earlier observational analyses suggesting its high gravity [11, 12]. Compared to the Alpha variant, infections with the Beta variant posed a 24% higher risk of severe disease, 49% higher risk of critical disease, and 57% higher risk of COVID-19 death.
These results explain the changing pattern of hospitalizations and deaths seen during the Beta wave compared to the Alpha wave (Figure 1). Acute-care admissions doubled during the Beta wave, but ICU admissions and deaths quadrupled, with the disproportionally greater effect of this variant on critical disease and COVID-19 death.
Number of A) daily new COVID-19 acute-care hospital admissions, B) daily new COVID-19 ICU hospital admissions, and C) COVID-19 deaths in Qatar.
Limitations include the smaller sample sizes of critical disease and COVID-19 deaths in the Alpha variant analysis (Supplementary Table 2) compared to the Beta variant analysis (Supplementary Table 3), as COVID-19 criticality and fatality have been low in Qatar’s predominantly young and working-age population [8, 13], leading to statistically non-significant results and wider 95% confidence intervals. Data on co-morbid conditions were not available to study investigators; hence, they could not be factored explicitly in our analysis. Nevertheless, matching and adjusting for age in analysis may have served as a proxy, given that co-morbidities are associated with old age. Furthermore, with the young population structure [8], we anticipate that only a small proportion of the study population may have had serious co-morbid conditions.
However, our findings may not be entirely generalizable to other settings, where elderly people constitute a sizable proportion of the population. Imperfect assay sensitivity and specificity of PCR testing may have affected infection ascertainment. However, all PCR testing was performed with extensively used, investigated, and validated commercial platforms having essentially 100% sensitivity and specificity (Supplementary Text 1). Unlike blinded, randomized clinical trials, the investigated observational cohorts were neither blinded nor randomized.
In conclusion, the Alpha variant is associated with 48% higher risk of severe disease than wild-type variants. In turn, the Beta variant is associated with 24% higher risk of severe disease than the Alpha variant, and strikingly, even higher risk of critical disease (49%) and COVID-19 death (57%). These findings highlight risks to healthcare systems, particularly intensive care facilities and resources, in the event of a globally increased circulation of the Beta variant.
Data Availability
The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.
Funding
The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health and Hamad Medical Corporation. The authors are also grateful for the Qatar Genome Programme for supporting the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.
Author contributions
LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript.
All authors have read and approved the final manuscript.
Competing interests
Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.
Data availability
The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.
Supplementary Material
Supplementary Text 1. Laboratory methods
Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIAsymphony platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kits (100% sensitivity and specificity [1]; Thermo Fisher Scientific, USA) on an ABI 7500 FAST (ThermoFisher, USA); extracted using a custom protocol [2] on a Hamilton Microlab STAR (Hamilton, USA) and tested using AccuPower SARS-CoV-2 Real-Time RT-PCR Kits (100% sensitivity and specificity [3]; Bioneer, Korea) on an ABI 7500 FAST; or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (95% sensitivity, 100% specificity [4]; Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab regions. The second targets the viral RdRp and E-gene regions, and the third targets the ORF1ab and E-gene regions.
All PCR tests were conducted at the Hamad Medical Corporation Central Laboratory or Sidra Medicine Laboratory, following standardized protocols.
Supplementary Text 2. COVID-19 severity, criticality, and fatality classification
Severe COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “oxygen saturation of <90% on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or ≥60 breaths/minute in children <2 months old or ≥50 breaths/minute in children 2–11 months old or ≥40 breaths/minute in children 1–5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)” [5]. Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report [5].
Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy” [5]. Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report [5].
COVID-19 death was defined per WHO classification as “a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19”. Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report [6].
Supplementary Text 3. Classification of infections by variant type
Classification of infections by variant type was informed by weekly rounds of viral genome sequencing and multiplex, real-time reverse-transcription PCR (RT-qPCR) variant screening [7] of randomly collected clinical samples [8–12], as well as by results of deep sequencing of wastewater samples [10]. Based on existing evidence [13–15] and confirmation with viral genome sequencing [16], an Alpha case was defined as an S-gene “target failure” using the TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific, USA [1]; >85% of PCR testing in Qatar) applying the criterion of a PCR cycle threshold (Ct) value ≤30 for both the N and ORF1ab genes, and a negative outcome for the S gene [15].
From January 18 until February 15, 2021, the weekly rounds of viral genome sequencing [8–11] identified presence of the Alpha variant and other originally circulating “wild-type” variants, but documented only limited presence of the Beta variant and no presence of other variants of concern [8–11]. Meanwhile, with essentially only Beta and Alpha cases identified from March 8, 2021 until the end of study (May 31, 2021) in the viral genome sequencing and multiplex RT-qPCR variant screening [8–12], a Beta case was proxied as the complement of Alpha criteria, that is, any infection with a Ct value ≤30 for the N, ORF1ab, and S genes. The Delta [17] (B.1.617.2) variant has been introduced only recently in Qatar, and it remains at low incidence as of July 11, 2021 [10–12]. There is no evidence that any other variant of concern is or has been responsible for appreciable community transmission in Qatar [10, 11].
STROBE checklist for case-control studies.
Assessment of the severity, criticality, and fatality of the Alpha variant compared to wild-type variants. Demographic characteristics of A) patients experiencing COVID-19 severe disease and controls (asymptomatic or mild SARS-CoV-2 infection), B) patients experiencing COVID-19 critical disease and controls (asymptomatic or mild SARS-CoV-2 infection), and C) cases resulting in COVID-19 death and controls (non-fatal infection).
Assessment of the severity, criticality, and fatality of the Beta variant compared to the Alpha variant. Demographic characteristics of A) patients experiencing COVID-19 severe disease and controls (asymptomatic or mild SARS-CoV-2 infection), B) patients experiencing COVID-19 critical disease and controls (asymptomatic or mild SARS-CoV-2 infection), and C) cases resulting in COVID-19 death and controls (non-fatal infection).
Sensitivity analyses for COVID-19 severity, criticality, and fatality in Qatar after A) adjusting for age in logistic regression analysis, and B) adjusting for age and sex in logistic regression analysis.
Acknowledgements
We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, and the Qatar Biobank for their diligent efforts and contributions to make this study possible.
